Phosphorylated 14-3-3zeta protein in the CSF of neuroleptic-treated patients

Neurology. 2005 May 10;64(9):1618-20. doi: 10.1212/01.WNL.0000160397.81314.84.

Abstract

The authors describe 12 neuroleptic-treated patients with dementia of various etiologies who showed CSF elevation of phosphorylated 14-3-3zeta and normal tau protein levels. This contrasted with elevated amounts of 14-3-3 gamma, epsilon, and unphosphorylated zeta coupled to high tau protein levels in Creutzfeldt-Jakob disease and negative 14-3-3 assay in drug-free patients with dementia. Characterization of CSF 14-3-3 isoforms and determination of tau protein level can help to distinguish different etiologies of dementia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 14-3-3 Proteins / cerebrospinal fluid*
  • Aged
  • Aged, 80 and over
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Biomarkers / cerebrospinal fluid
  • Brain / metabolism
  • Brain / physiopathology
  • Creutzfeldt-Jakob Syndrome / cerebrospinal fluid
  • Creutzfeldt-Jakob Syndrome / diagnosis
  • Dementia / cerebrospinal fluid*
  • Dementia / diagnosis*
  • Dementia / drug therapy
  • Diagnosis, Differential
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phosphorylation
  • Predictive Value of Tests
  • Protein Isoforms / cerebrospinal fluid
  • Reference Values
  • Up-Regulation / physiology
  • tau Proteins / cerebrospinal fluid*

Substances

  • 14-3-3 Proteins
  • Antipsychotic Agents
  • Biomarkers
  • Protein Isoforms
  • tau Proteins